|
[Related PubMed/MEDLINE]
Total Number of Papers: 423
|
|
|
| |
|
[Display Entries]
|
|
>> all entries
|
| |
|
[Entries Per Page]
|
|
per page
|
| |
|
Page Control
|
|
|
| Page: of |
|
|
|
| No. |
Year |
Title |
Co-occurring Abbreviation |
| 1 |
2020 |
Active Compound of Pharbitis Semen (Pharbitis nil Seeds) Suppressed KRAS-Driven Colorectal Cancer and Restored Muscle Cell Function during Cancer Progression. |
CRC, PN |
| 2 |
2020 |
Anti-Metastatic Activity of an Anti-EGFR Monoclonal Antibody against Metastatic Colorectal Cancer with KRAS p.G13D Mutation. |
CRC, EGFR, mCRC |
| 3 |
2020 |
Association of BMI and major molecular pathological markers of colorectal cancer in men and women. |
BRAF, CIMP, CRC, MSI |
| 4 |
2020 |
Association of histologic subtypes with genetic alteration and PD-L1 expression in pulmonary adenocarcinoma. |
ADC, EGFR, NGS, PD-L1 |
| 5 |
2020 |
Beyond the Genomic Mutation: Rethinking the Molecular Biomarkers of K-RAS Dependency in Pancreatic Cancers. |
PDAC |
| 6 |
2020 |
BRAF and KRAS mutations in metastatic colorectal cancer: future perspectives for personalized therapy. |
CRC, mCRC |
| 7 |
2020 |
Circulating tumor DNA analysis in the era of precision oncology. |
ctDNA, EGFR |
| 8 |
2020 |
Construction of a reference material panel for detecting KRAS/NRAS/EGFR/BRAF/MET mutations in plasma ctDNA. |
BRAF, cfDNA, ctDNA, EGFR, MET, NGS, NRAS, NSCLC, PIK3CA, RM |
| 9 |
2020 |
Differences in Pathology and Mutation Status Among Colorectal Cancer Patients Younger Than, Older Than, and of Screening Age. |
RAS, SA |
| 10 |
2020 |
ERK Dephosphorylation through MKP1 Deacetylation by SIRT1 Attenuates RAS-Driven Tumorigenesis. |
ERK, MAPK |
| 11 |
2020 |
ERK phosphorylation as a marker of RAS activity and its prognostic value in non-small cell lung cancer. |
EGFR, NSCLC, OS, p-Akt, p-ERK |
| 12 |
2020 |
Genotype Driven Therapy for Non-Small Cell Lung Cancer: Resistance, Pan Inhibitors and Immunotherapy. |
ALK, EGFR, NSCLC, TKI |
| 13 |
2020 |
Human papillomavirus-negative epithelial proliferations resembling condylomata acuminata in a patient receiving vemurafenib for Stage IV melanoma. |
HRAS, NRAS |
| 14 |
2020 |
In vivo imaging of cell proliferation in meningioma using 3'-deoxy-3'-[18F]fluorothymidine PET/MRI. |
PCNA, PET, phh3, TIMP3, TK1, Vb, VEGF-A, WHO |
| 15 |
2020 |
KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne? |
CNS, GTP, NSCLC |
| 16 |
2020 |
KRAS G12C Metastatic Colorectal Cancer: Specific Features of a New Emerging Target Population. |
CRCs, mCRC |
| 17 |
2020 |
KRAS mutations testing in non-small cell lung cancer: the role of Liquid biopsy in the basal setting. |
EGFR, NGS, NSCLC |
| 18 |
2020 |
KRAS oncogene may be another target conquered in non-small cell lung cancer (NSCLC). |
NSCLC |
| 19 |
2020 |
Metabolic characterization of colorectal cancer cells harbouring different KRAS mutations in codon 12, 13, 61 and 146 using human SW48 isogenic cell lines. |
ANOVA, CRC, FDR |
| 20 |
2020 |
Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer. |
ALK, EGFR, NSCLC, PD-1, PD-L1, TILs |
| 21 |
2020 |
Multicenter Single-Arm, Two-Stage Phase 2 Study of Panitumumab in Patients With Cetuximab-Refractory Metastatic Colorectal Cancer: The PACER Trial. |
mCRC, RAS |
| 22 |
2020 |
Myotubularin-related protein 7 activates peroxisome proliferator-activated receptor-gamma. |
CC, PPARgamma, SRC1 |
| 23 |
2020 |
Next-Generation Radiogenomics Sequencing for Prediction of EGFR and KRAS Mutation Status in NSCLC Patients Using Multimodal Imaging and Machine Learning Algorithms. |
AUC, CT, CTD, EGFR, FDR, LoG, MTV, NSCLC, PCR, PET, SGD, SM, SUV, VT |
| 24 |
2020 |
Noninvasive KRAS mutation estimation in colorectal cancer using a deep learning method based on CT imaging. |
AUC, CRC, DL, ResNet, RFC, ROI |
| 25 |
2020 |
Overexpression of BMP1 reflects poor prognosis in clear cell renal cell carcinoma. |
BMP, ccRCC, DFS, EMT, GSEA, OS |
| 26 |
2020 |
Pathologic complete response to preoperative immunotherapy in a lung adenocarcinoma patient with bone metastasis: A case report. |
ALK, DDR, EGFR, ICIs, NSCLC, PD-1, TP53 |
| 27 |
2020 |
Positive Correlation Between Somatic Mutations in RAS Gene and Colorectal Cancer in Telangana Population: Hospital-Based Study in a Cosmopolitan City. |
CRC, EGFR, NRAS |
| 28 |
2020 |
Prognostic Value of KRAS Mutation Subtypes and PD-L1 Expression in Patients With Lung Adenocarcinoma. |
LADC, OS, PD-L1 |
| 29 |
2020 |
Small Molecule KRAS Inhibitors: The Future for Targeted Pancreatic Cancer Therapy? |
PDAC |
| 30 |
2020 |
Successful Multidisciplinary Treatment for Aggressive Primary Pulmonary Undifferentiated Pleomorphic Sarcoma. |
CT, MFH, UPS |
| 31 |
2020 |
Targeting KRAS Mutant Non-Small-Cell Lung Cancer: Past, Present and Future. |
NSCLC |
| 32 |
2020 |
Targeting UHRF1-dependent DNA repair selectively sensitizes KRAS mutant lung cancer to chemotherapy. |
DSB |
| 33 |
2020 |
The Addition of EGFR Inhibitors in Neoadjuvant Therapy for KRAS-Wild Type Locally Advanced Rectal Cancer Patients: A Systematic Review and Meta-Analysis. |
EGFR, LARC, NCCN, nCRT, TME |
| 34 |
2020 |
The effect of MEK1/2 inhibitors on cisplatin-induced acute kidney injury (AKI) and cancer growth in mice. |
AKI, ATN, CDK4, LC3-II, NSCLC, PD-L1 |
| 35 |
2020 |
The Functional Effects of Key Driver KRAS Mutations on Gene Expression in Lung Cancer. |
IFS, mRMR |
| 36 |
2020 |
The prognostic value of Kirsten rat sarcoma viral oncogene homolog mutations in resected lung adenocarcinoma differs according to clinical features. |
CI, HR, OS, RFS |
| 37 |
2020 |
Undetectable RAS-Mutant Clones in Plasma: Possible Implication for Anti-EGFR Therapy and Prognosis in Patients With RAS-Mutant Metastatic Colorectal Cancer. |
ctDNA, EGFR, mCRC, NRAS, RAS-mt, RAS-WT |
| 38 |
2020 |
[Analysis of Clinical Characteristics and Driver Genes in 405 Patients with Lung Cancer Complicated with Tuberculosis]. |
ALK, CT, EGFR, ROS1 |
| 39 |
2020 |
[Genetic Profile of Young Chinese Patients with Lung Adenocarcinoma]. |
ALK, EGFR, EGFR-TKI, HER2, NGS, STK11, TP53 |
| 40 |
2019 |
18F-FDG PET/CT imaging in pulmonary sarcomatoid carcinoma and correlation with clinical and genetic findings. |
MTV, PD-L1, PFS, PSC, TLG |
| 41 |
2019 |
A rare case of synchronous ovarian tumors: clinical case report and literature review. |
HP, NRAS |
| 42 |
2019 |
Anti-MEK and Anti-EGFR mAbs in RAS-Mutant Metastatic Colorectal Cancer: Case Series and Rationale. |
ERK |
| 43 |
2019 |
Association between methylation of DNA damage response-related genes and DNA damage in hepatocytes of rats following subchronic exposure to vinyl chloride. |
CDKN, MGMT, SYK, VC |
| 44 |
2019 |
Association of Aspirin and Nonsteroidal Anti-Inflammatory Drugs With Colorectal Cancer Risk by Molecular Subtypes. |
BRAF, CIs, CRC, MSI, NSAIDs, ORs |
| 45 |
2019 |
Colorectal Cancer Prognosis is Not Associated with BRAF and KRAS Mutations-A STROBE Compliant Study. |
CRC, DFS, OS |
| 46 |
2019 |
Combination therapy with KRAS siRNA and EGFR inhibitor AZD8931 suppresses lung cancer cell growth in vitro. |
EGFR, siRNA |
| 47 |
2019 |
Comparison of Clinicopathological Features and Prognosis between ALK Rearrangements and EGFR Mutations in Surgically Resected Early-stage Lung Adenocarcinoma. |
ALK, DFS, EGFR, LAC, OS, RT, WT |
| 48 |
2019 |
Concomitant RAS and BRAF mutation in colorectal cancer - A report of 7 cases. |
CRC, RAS |
| 49 |
2019 |
Consistency and reproducibility of next-generation sequencing in cytopathology: A second worldwide ring trial study on improved cytological molecular reference specimens. |
AFs, BRAF, EGFR, NGS |
| 50 |
2019 |
CT texture analysis for the prediction of KRAS mutation status in colorectal cancer via a machine learning approach. |
CT, FDG, PET, ROC |
| 51 |
2019 |
Current Approaches in NSCLC Targeting K-RAS and EGFR. |
EGFR, NSCLC, TK |
| 52 |
2019 |
Diagnostic performance of F-18 FDG PET/CT for prediction of KRAS mutation in colorectal cancer patients: a systematic review and meta-analysis. |
CRC, DOR, FDG, LR, PET/CT, ROC |
| 53 |
2019 |
Dual-energy spectral CT characteristics in surgically resected lung adenocarcinoma: comparison between Kirsten rat sarcoma viral oncogene mutations and epidermal growth factor receptor mutations. |
DESCT, EGFR, NIC, NWC |
| 54 |
2019 |
Exposure of the extracellular matrix and colonization of the ovary in metastasis of fallopian-tube-derived cancer. |
FTE, HGSOC, MOE, PTEN |
| 55 |
2019 |
Genotyping and cytomorphological subtyping of lung adenocarcinoma based on liquid-based cytology. |
ADC, ALK, EGFR, FISH, IHC, LBC, ROS1 |
| 56 |
2019 |
HAO2 inhibits malignancy of clear cell renal cell carcinoma by promoting lipid catabolic process. |
ccRCC, DFS, EMT, GSEA, HAO2, OS |
| 57 |
2019 |
Kirsten Rat Sarcoma Viral Oncogene Homologue (KRAS) Mutations in the Occurrence and Treatment of Pancreatic Cancer. |
--- |
| 58 |
2019 |
MicroRNA-217 acts as a tumor suppressor and correlates with the chemoresistance of cervical carcinoma to cisplatin. |
miR-217 |
| 59 |
2019 |
MiR-223-3p promotes cell proliferation and metastasis by downregulating SLC4A4 in clear cell renal cell carcinoma. |
miRNAs, SLC4A4 |
| 60 |
2019 |
Molecular association of functioning stroma with carcinoma cells in the ovary: A preliminary study. |
ARID1A, PIK3CA, PTEN |
| 61 |
2019 |
Molecular Subtypes Are Frequently Discordant Between Lesions in Patients With Synchronous Colorectal Cancer: Molecular Analysis of 59 Patients. |
CRC, MLH1, TP53 |
| 62 |
2019 |
Not all mutations of KRAS predict poor prognosis in patients with colorectal cancer. |
CRC, OS, PFS |
| 63 |
2019 |
Phenotypic Switching of Naive T Cells to Immune-Suppressive Treg-Like Cells by Mutant KRAS. |
MT, NSCLC |
| 64 |
2019 |
Plinabulin, an inhibitor of tubulin polymerization, targets KRAS signaling through disruption of endosomal recycling. |
ERK |
| 65 |
2019 |
Potential function of microRNAs in thoracic aortic aneurysm and thoracic aortic dissection pathogenesis. |
MAPK, TAA, TAD, TAGLN |
| 66 |
2019 |
Programmed cell death ligand 1 expression in cytologic and surgical non-small cell lung carcinoma specimens from a single institution: Association with clinicopathologic features and molecular alterations. |
NSCLC, PD-L1 |
| 67 |
2019 |
Quantitative features of dual-energy spectral computed tomography for solid lung adenocarcinoma with EGFR and KRAS mutations, and ALK rearrangement: a preliminary study. |
ALK, DESCT, EGFR, IC, WC |
| 68 |
2019 |
RAS mutation: site of disease and recurrence pattern in colorectal cancer. |
CRC, LiM, OS, RFS |
| 69 |
2019 |
Strategies to target energy metabolism in consensus molecular subtype 3 along with Kirsten rat sarcoma viral oncogene homolog mutations for colorectal cancer therapy. |
CMSs, CRC |
| 70 |
2019 |
Targeting oxidative pentose phosphate pathway prevents recurrence in mutant Kras colorectal carcinomas. |
CDCP1, CRCs, CSCs, PPP, ROS, Sirt5, TPI |
| 71 |
2019 |
The expression of circulating miR-504 in plasma is associated with EGFR mutation status in non-small-cell lung carcinoma patients. |
AUC, EGFR, miRNAs, NSCLC |
| 72 |
2019 |
The Role of KRAS in Endometrial Cancer: A Mini-Review. |
EC, MAPK |
| 73 |
2019 |
Transistor-like Ultra-pH-Sensitive Polymeric Nanoparticles. |
UPS |
| 74 |
2019 |
Use of cell free DNA as a prognostic biomarker in non-small cell lung cancer patients with bone metastasis. |
NSCLC |
| 75 |
2018 |
Aberrant status and clinicopathologic characteristic associations of 11 target genes in 1,321 Chinese patients with lung adenocarcinoma. |
ALK, BRAF, EGFR, GGN, GGO, HER2, PD-1, PD-L1, PIK3CA |
| 76 |
2018 |
Afatinib restrains K-RAS-driven lung tumorigenesis. |
EGFR, NSCLC, TKIs |
| 77 |
2018 |
Association between EGFR/KRAS mutation and expression of VEGFA, VEGFR and VEGFR2 in lung adenocarcinoma. |
EGFR, VEGF, VEGFR |
| 78 |
2018 |
beta-Catenin maintains lung epithelial progenitors after lung specification. |
FGF, GI, NKX2-1, SOX2, SOX9, TRAP |
| 79 |
2018 |
Clinicopathologic characteristics and survival outcome in patients with advanced lung adenocarcinoma and KRAS mutation. |
OS, PFS, TMB |
| 80 |
2018 |
Clinicopathological Characteristics and KRAS Mutation Status of Endometrial Mucinous Metaplasia and Carcinoma. |
--- |
| 81 |
2018 |
Comparative analysis of immune checkpoint inhibitors and chemotherapy in the treatment of advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials. |
CI, CNS, ECOG PS, EGFR, NSCLC, OR, ORR, OS, PD-L1, PD1, PFS, RCTs, TRAEs |
| 82 |
2018 |
Comparison of CT radiogenomic and clinical characteristics between EGFR and KRAS mutations in lung adenocarcinomas. |
CI, CT, EGFR, OR |
| 83 |
2018 |
Cordyceps militaris Grown on Germinated Soybean Suppresses KRAS-Driven Colorectal Cancer by Inhibiting the RAS/ERK Pathway. |
ERK |
| 84 |
2018 |
Could IVIM and ADC help in predicting the KRAS status in patients with rectal cancer? |
ROC |
| 85 |
2018 |
Detection of EGFR, KRAS and BRAF mutations in metastatic cells from cerebrospinal fluid. |
CSF, EGFR, HER2, PCR |
| 86 |
2018 |
Determination of CEBPA mutations by next generation sequencing in pediatric acute leukemia. |
Cbl, CEBPA, JAK2, NPM1, TET2 |
| 87 |
2018 |
Diagnosis, clinicopathological characteristics and prognosis of pulmonary mucinous adenocarcinoma. |
EGFR, PPMA |
| 88 |
2018 |
Double KRAS and BRAF Mutations in Surgically Treated Colorectal Cancer Liver Metastases: An International, Multi-institutional Case Series. |
CRC, CRLM |
| 89 |
2018 |
Effectiveness of Cetuximab as First-Line Therapy for Patients With Wild-Type KRAS and Unresectable Metastatic Colorectal Cancer in Real-Life Practice: Results of the EREBUS Cohort. |
mCRC, OS |
| 90 |
2018 |
EGFR, KRAS, BRAF, PTEN, and PIK3CA mutation in plasma of small cell lung cancer patients. |
EGFR, PIK3CA, PTEN, SCLC |
| 91 |
2018 |
Emerging application of genomics-guided therapeutics in personalized lung cancer treatment. |
ALK, EGFR, NSCLC, ROS1, SCLC |
| 92 |
2018 |
Genomic Characteristics of Invasive Mucinous Adenocarcinomas of the Lung and Potential Therapeutic Targets of B7-H3. |
EGFR, IMA, PD-L1, TP53 |
| 93 |
2018 |
Heterogeneity of PD-L1 Expression and Relationship with Biology of NSCLC. |
ALK, EGFR, EML4, NSCLC, PD-L1 |
| 94 |
2018 |
Hotspot Mutations Detectable by Next-generation Sequencing in Exhaled Breath Condensates from Patients with Lung Cancer. |
APC, DDR2, EBC, EGFR, ERBB4, FBXW7, FGFR1, FGFR3, MET, NGS, PIK3CA, PTEN, RET, SMAD4, STK11, TP53 |
| 95 |
2018 |
Intraductal papillary mucinous neoplasms of the pancreas: Clinical association with KRAS. |
IPMN |
| 96 |
2018 |
KRAS-Mutant non-small cell lung cancer: From biology to therapy. |
NSCLC |
| 97 |
2018 |
Liver dual arterial blood supply maintains liver regeneration: Analysis of signaling pathways in rats. |
LDABS, LRR, Mapk10, PCR, PH, RB1 |
| 98 |
2018 |
Long-term survival with erlotinib in advanced lung adenocarcinoma harboring synchronous EGFR G719S and KRAS G12C mutations. |
EGFR, NSCLC, TKIs |
| 99 |
2018 |
Loss of ARID1A Expression Correlates With Tumor Differentiation and Tumor Progression Stage in Pancreatic Ductal Adenocarcinoma. |
Bcl-2, miR-31 |
| 100 |
2018 |
MerTK mediates STAT3-KRAS/SRC-signaling axis for glioma stem cell maintenance. |
CSC, GBM, STAT3 |
|
A Search Service for Abbreviation / Long Form
